RGMA: Repulsive guidance molecule A
Member of the repulsive guidance molecule (RGM) family that performs several functions in the developing and adult nervous system.
- Drugs that act on it: 2
- Approved: 0
- In phases 1 to 3: 2
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on RGMA, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Antibody 2
| Elezanumab | Phase 2 | AbbVie | Antibody | InhibitorRepulsive guidance molecule A inhibitor | 0 |
| Unasnemab | Phase 2 | — | Antibody | InhibitorRepulsive guidance molecule A inhibitor | 0 |
- Osteoarthritis, hip0.39
- Placental abruption0.35
- Diabetes mellitus0.34
- Pregnancy disorder0.33
- Medical procedure0.31
- COVID-190.31
- Abnormality of the skeletal system0.30
- Ocular hypotension0.29
- Cervical carcinoma0.29
- Type 2 diabetes mellitus0.29
- Cardiomyopathy0.27
- Brain compression0.23
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4630886, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt Q96B86, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets